Construction method of NKT cell lymphoma individualized prognosis model based on mononucleotide

Abstract

The invention specifically discloses a construction method of an NKT cell lymphoma individualized prognosis model based on mononucleotide. The construction method comprises the following steps: collecting a certain number of internal blood specimens of NKTCL cell lymphoma patients, detecting the SNP state of the specimens through an Illumina Asian Screening Array chip, obtaining differential SNP sites by using chi-square test, and taking the differential SNP sites as an original data set; dividing the original data set into a verification set and an internal training set; the internal training set is combined with clinical indexes, a nomogram prognosis initial model is constructed through multi-factor Lasso-cox high-dimensional data linear regression analysis, and the nomogram prognosis initial model is preliminarily verified through a verification set; the method comprises the following steps: collecting an external formalin-fixed paraffin embedding (FFPE) NKTCL tissue case with complete follow-up visit data as an external training set, and training a nomogram prognosis initial model by adopting the external training set; and the initial model is predicted, and a final nomogram prognosis model is obtained after verification. The method can guide precise treatment to save medical resources, relieve the burden of a patient and reduce the treatment side reaction of the patient.

Description

technical field [0001] The invention relates to the technical field of cancer risk assessment, in particular to a method for constructing an individualized prognosis model of NKT cell lymphoma based on a single nucleotide. Background technique [0002] NK / T-cell lymphoma (NKTCL) is a subtype of non-Hodgkin's lymphoma, with the highest incidence in my country worldwide. Tissue necrosis in NKTCL lesions is obvious, which brings certain difficulties to the definite diagnosis of NKTCL. In addition, NKTCL individuals are highly heterogeneous. The current prognosis evaluation system is mostly based on clinical and pathological features. Patients with the same clinical stage often show significant differences in prognosis. In terms of treatment, the current prognostic evaluation system cannot guide the precise diagnosis and treatment of patients. The guidelines recommend that patients with early-stage NKTCL receive combined chemotherapy and radiotherapy or radiotherapy alone, but t...

AI Technical Summary

Problems solved by technology

1. At present, the prognosis of NKTCL mainly uses PINK, PINK-E, IPI and other prognosis evaluation systems based on clinical and pathological characteristics, which cannot explain the root cause of the differential prognosis;

2. Some studies have tried to explore the gene mutation and transcriptome characteristics of NKTCL, but due to the obvious tissue necrosis in the lesion of NKTCL, it is impossible to rule out the deviation of the quality of the sample, the location of the sample, and the heterogeneity of the tumor;

3. The current prognosis evaluation system fails to assist patients with early NKTCL to choose combined radiotherapy and chemotherapy or radiotherapy alone, and cannot guide precise treatment decisions

Images